Century Therapeutics Q3 net loss narrows, beats analyst expectations
Overview
US biotechnology firm's Q3 net loss narrowed and beat analyst expectations
Operating income for Q3 missed analyst expectations
R&D expenses fell yr/yr due to portfolio prioritization and lower facility costs
Outlook
Century expects to submit IND for CNTY-813 in 4Q 2026
Company anticipates initial clinical data for CNTY-813 in 2H 2027
Century estimates cash runway into 1Q 2029
Result Drivers
R&D EXPENSES - Co said lower R&D expenses were due to reduced personnel and facility costs following portfolio prioritization
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | Beat | $23.45 mln | $24.25 mln (5 Analysts) |
Q3 Operating Income | Miss | -$25.21 mln | -$24.71 mln (6 Analysts) |
Q3 Loss Per Basic Share | $0.11 | ||
Q3 Operating Expenses | $25.21 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Century Therapeutics, Inc. is $5.00, about 187.4% above its November 11 closing price of $1.74
Reuters Recommended Reads
Nov 10 - Biomea Fusion Q3 net loss narrows on lower R&D expenses
Nov 9 - Editas Medicine Q3 net loss narrows
Nov 10 - Atara Biotherapeutics Q3 revenue beats estimates as costs decline
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)